Park Square is pleased to announce the placement of Dr. Peter Fekkes as Vice President, Discovery at 54gene, a precision medicine company dedicated to improving the inclusion of African populations in global genomics research.

Peter brings a wealth of experience in novel drug discovery and development, having most recently served as Vice President, Discovery Bioscience at FogPharma. Previously, he served as Head of New Targets Platform at HotSpot Therapeutics. Earlier in his career he held roles of increasing responsibility at the Novartis Institutes for BioMedical Research.

Peter will be working alongside Colm O’Dushlaine, Vice President, Genomics and Data Science at 54gene, whom Park Square placed previously, to translate findings from the company’s proprietary genomics dataset into novel drug discovery programs.

Peter holds a Ph.D. in Biochemistry and Molecular Biology and an M.S. in Biology from University of Groningen.